Author of

• 20166

  +

  P1.17 - Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies (ID 703)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22843

    +

    P1.17-013 - Prognostic Impact of Programmed Cell Death-1 (PD-1) and PD-Ligand 1 (PD-L1) Expression in Thymic Cancer (ID 9655)

    09:30 - 09:30  |  Presenting Author(s): Soichiro Funaki
    • Abstract
    • Slides

    Background:
    Thymic cancer is one of the aggressive thoracic malignancies. Chemotherapy, radiation therapy, and surgery are the main therapeutic options. However, no standard therapy has not been established because of the rarity, and the mortality rate remains high. Therefore, additional therapeutic options are needed. Recently, cancer immunotherapy has been developed and shown promising results against some malignancies in clinical trials. One of the immuno-check point proteins; the programmed cell death 1/ Programmed cell death 1-Ligand 1 (PD-1/PD-L1) pathways play one of the main role in cancer immunology. The expression of PD-L1 in cancer cells and PD-1 positive tumor infiltrating lymphocytes (TIL) are reportedly one of the useful prognostic and predictive factor for the therapeutic effect of anti-PD-1 or anti-PD-L1 immunotherapies in several malignancies. However, clinical significance of PD-1 and PD-L1 in thymic cancer remains unclear. In this present study, we retrospectively investigated the relationships between the expression of PD/1PD-L1 and clinical backgrounds in thymic cancer.
    
    Method:
    A total of 30 patients of thymic cancer surgically resected from 1998 to 2016 in our institutes were retrospectively analyzed. Median follow up periods was 4.2 years. The expression of PD-L1 and PD-1positve TIL was evaluated by immunohistochemical staining using formalin-fixed paraffin embedded surgically resected tissues and analyzed the relationships between those expressions and clinical backgrounds. A Pearson's chi-square test was used to compare the variances. Disease-free survival (DFS) were analyzed by using the Kaplan–Meier method, and the Log-rank test was used to compare the survival distributions of subgroup.
    
    Result:
    14 cases were positive in immunohistochemistry staining of PD-L1 (47%). While, 16 cases were positive in PD-1 TIL staining (55%). There were no significant relationships between PD-1/PD-L1 positive staining and Masaoka-Koga stage. In tumor size, age and gender, there were also no significant difference among IHC results of PD-1/PD-L1. While, in disease free survival rate (DFS), the PD-1 and PD-L1-positive cases were significantly worse as compared to negative cases (PD-1; P=0.001, PD-L1; P=0.03). Uni- and multivariant analysis showed the PD-1 and PD-L1 expression were independent prognostic factors (P < 0.05).
    
    Conclusion:
    Our results suggested that the high PD-L1 expression and the PD-1 positive TIL are indicators of poor prognosis, and anti PD-1/PD-L1 immunotherapy may be reliable option to treatment in thymic cancer.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.